|
1
|
Modak S and Cheung N-K: Neuroblastoma:
Therapeutic strategies for a clinical enigma. Cancer Treat Rev.
36:307–317. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Iżycka-Świeszewska E, Drożyńska E, Rzepko
R, Kobierska-Gulida G, Grajkowska W, Perek D and Balcerska A:
Analysis of PI3K/AKT/mTOR signalling pathway in high risk
neuroblastic tumours. Pol J Pathol. 61:192–198. 2010.
|
|
3
|
Cheung N-KV and Dyer MA: Neuroblastoma:
Developmental biology, cancer genomics and immunotherapy. Nat Rev
Cancer. 13:397–411. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hara J: Development of treatment
strategies for advanced neuroblastoma. Int J Clin Oncol.
17:196–203. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu AL, Gilman AL, Ozkaynak MF, London WB,
Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay
KK, et al; Children's Oncology Group. Anti-GD2 antibody with
GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J
Med. 363:1324–1334. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aixinjueluo W and Furukawa K, Zhang Q,
Hamamura K, Tokuda N, Yoshida S, Ueda R and Furukawa K: Mechanisms
for the apoptosis of small cell lung cancer cells induced by
anti-GD2 monoclonal antibodies: Roles of anoikis. J Biol Chem.
280:29828–29836. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoshida S, Kawaguchi H, Sato S, Ueda R and
Furukawa K: An anti-GD2 monoclonal antibody enhances apoptotic
effects of anti-cancer drugs against small cell lung cancer cells
via JNK (c-Jun terminal kinase) activation. Jpn J Cancer Res.
93:816–824. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kowalczyk A, Gil M, Horwacik I, Odrowąż Z,
Kozbor D and Rokita H: The GD2-specific 14G2a monoclonal antibody
induces apoptosis and enhances cytotoxicity of chemotherapeutic
drugs in IMR-32 human neuroblastoma cells. Cancer Lett.
281:171–182. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Horwacik I, Durbas M, Boratyn E, Węgrzyn P
and Rokita H: Targeting GD2 ganglioside and Aurora A kinase as a
dual strategy leading to cell death in cultures of human
neuroblastoma cells. Cancer Lett. 341:248–264. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cochonneau D, Terme M, Michaud A,
Dorvillius M, Gautier N, Frikeche J, Alvarez-Rueda N, Bougras G,
Aubry J, Paris F, et al: Cell cycle arrest and apoptosis induced by
O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth
in vitro and in vivo. Cancer Lett. 333:194–204. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Samuels Y and Ericson K: Oncogenic PI3K
and its role in cancer. Curr Opin Oncol. 18:77–82. 2006. View Article : Google Scholar
|
|
12
|
Fruman DA and Rommel C: PI3K and cancer:
Lessons, challenges and opportunities. Nat Rev Drug Discov.
13:140–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang L, Zhou F and ten Dijke P: Signaling
interplay between transforming growth factor-β receptor and
PI3K/AKT pathways in cancer. Trends Biochem Sci. 38:612–620. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hers I, Vincent EE and Tavaré JM: Akt
signalling in health and disease. Cell Signal. 23:1515–1527. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rodon J, Dienstmann R, Serra V and
Tabernero J: Development of PI3K inhibitors: Lessons learned from
early clinical trials. Nat Rev Clin Oncol. 10:143–153. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dienstmann R, Rodon J, Serra V and
Tabernero J: Picking the point of inhibition: A comparative review
of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 13:1021–1031.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Suzuki YJ, Mizuno M and Packer L: Signal
transduction for nuclear factor-kappa B activation. Proposed
location of antioxidant-inhibitable step. J Immunol. 153:5008–5015.
1994.PubMed/NCBI
|
|
19
|
Niehrs C: The complex world of WNT
receptor signalling. Nat Rev Mol Cell Biol. 13:767–779. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koul HK, Pal M and Koul S: Role of p38 MAP
kinase signal transduction in solid tumors. Genes Cancer.
4:342–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu Y, Gorospe M, Yang C and Holbrook NJ:
Role of mitogen-activated protein kinase phosphatase during the
cellular response to genotoxic stress. Inhibition of c-Jun
N-terminal kinase activity and AP-1-dependent gene activation. J
Biol Chem. 270:8377–8380. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Davison K, Mann KK, Waxman S and Miller WH
Jr: JNK activation is a mediator of arsenic trioxide-induced
apoptosis in acute promyelocytic leukemia cells. Blood.
103:3496–3502. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cuadrado A and Nebreda AR: Mechanisms and
functions of p38 MAPK signalling. Biochem J. 429:403–417. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Walsh MF, Thamilselvan V, Grotelueschen R,
Farhana L and Basson M: Absence of adhesion triggers differential
FAK and SAPKp38 signals in SW620 human colon cancer cells that may
inhibit adhesiveness and lead to cell death. Cell Physiol Biochem.
13:135–146. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Darnell JE Jr, Kerr IM and Stark GR:
Jak-STAT pathways and transcriptional activation in response to
IFNs and other extracellular signaling proteins. Science.
264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Beierle EA, Ma X, Stewart J, Nyberg C,
Trujillo A, Cance WG and Golubovskaya VM: Inhibition of focal
adhesion kinase decreases tumor growth in human neuroblastoma. Cell
Cycle. 9:1005–1015. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Motti ML, De Marco C, Califano D, Fusco A
and Viglietto G: Akt-dependent T198 phosphorylation of
cyclin-dependent kinase inhibitor p27kip1 in breast cancer. Cell
Cycle. 3:1074–1080. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Viglietto G, Motti ML and Fusco A:
Understanding p27(kip1) deregulation in cancer: Down-regulation or
mislocalization. Cell Cycle. 1:394–400. 2002. View Article : Google Scholar
|
|
29
|
Pourmand G, Ziaee AA, Abedi AR, Mehrsai A,
Alavi HA, Ahmadi A and Saadati HR: Role of PTEN gene in progression
of prostate cancer. Urol J. 4:95–100. 2007.PubMed/NCBI
|
|
30
|
Guertin DA, Stevens DM, Saitoh M, Kinkel
S, Crosby K, Sheen JH, Mullholland DJ, Magnuson MA, Wu H and
Sabatini DM: mTOR complex 2 is required for the development of
prostate cancer induced by Pten loss in mice. Cancer Cell.
15:148–159. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang Z, Yuan XG, Chen J, Luo SW, Luo ZJ
and Lu NH: Reduced expression of PTEN and increased PTEN
phosphorylation at residue Ser380 in gastric cancer tissues: A
novel mechanism of PTEN inactivation. Clin Res Hepatol
Gastroenterol. 37:72–79. 2013. View Article : Google Scholar
|
|
32
|
Robertson BW, Bonsal L and Chellaiah MA:
Regulation of Erk1/2 activation by osteopontin in PC3 human
prostate cancer cells. Mol Cancer. 9:2602010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chiang GG and Abraham RT: Phosphorylation
of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by
p70S6 kinase. J Biol Chem. 280:25485–25490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hong S, Zhao B, Lombard DB, Fingar DC and
Inoki K: Crosstalk between sirtuin and mammalian target of
rapamycin complex 1 (mTORC1) signaling in the regulation of S6
kinase 1 (S6K1) phosphorylation. J Biol Chem. 289:13132–13141.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dufner A and Thomas G: Ribosomal S6 kinase
signaling and the control of translation. Exp Cell Res.
253:100–109. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pullen N and Thomas G: The modular
phosphorylation and activation of p70s6k. FEBS Lett. 410:78–82.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pearson RB, Dennis PB, Han JW, Williamson
NA, Kozma SC, Wettenhall RE and Thomas G: The principal target of
rapamycin-induced p70s6k inactivation is a novel phosphorylation
site within a conserved hydrophobic domain. EMBO J. 14:5279–5287.
1995.PubMed/NCBI
|
|
38
|
Dowling RJ, Topisirovic I, Alain T,
Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj
A, Liu Y, et al: mTORC1-mediated cell proliferation, but not cell
growth, controlled by the 4E-BPs. Science. 328:1172–1176. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sonenberg N and Hinnebusch AG: Regulation
of translation initiation in eukaryotes: Mechanisms and biological
targets. Cell. 136:731–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kahn BB, Alquier T, Carling D and Hardie
DG: AMP-activated protein kinase: Ancient energy gauge provides
clues to modern understanding of metabolism. Cell Metab. 1:15–25.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mitchelhill KI, Michell BJ, House CM,
Stapleton D, Dyck J, Gamble J, Ullrich C, Witters LA and Kemp BE:
Posttranslational modifications of the 5′-AMP-activated protein
kinase β1 subunit. J Biol Chem. 272:24475–24479. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ha J, Daniel S, Broyles SS and Kim KH:
Critical phosphorylation sites for acetyl-CoA carboxylase activity.
J Biol Chem. 269:22162–22168. 1994.PubMed/NCBI
|
|
43
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Osaki M, Oshimura M and Ito H: PI3K-Akt
pathway: Its functions and alterations in human cancer. Apoptosis.
9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Akinleye A, Avvaru P, Furqan M, Song Y and
Liu D: Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer
therapeutics. J Hematol Oncol. 6:882013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Maira SM, Stauffer F, Brueggen J, Furet P,
Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker
K, et al: Identification and characterization of NVP-BEZ235, a new
orally available dual phosphatidylinositol 3-kinase/mammalian
target of rapamycin inhibitor with potent in vivo antitumor
activity. Mol Cancer Ther. 7:1851–1863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chanthery YH, Gustafson WC, Itsara M,
Persson A, Hackett CS, Grimmer M, Charron E, Yakovenko S, Kim G,
Matthay KK, et al: Paracrine signaling through MYCN enhances
tumor-vascular interactions in neuroblastoma. Sci Transl Med.
4:115ra32012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Seitz C, Hugle M, Cristofanon S,
Tchoghandjian A and Fulda S: The dual PI3K/mTOR inhibitor
NVP-BEZ235 and chloroquine synergize to trigger apoptosis via
mitochondrial-lysosomal cross-talk. Int J Cancer. 132:2682–2693.
2013. View Article : Google Scholar
|
|
49
|
Garcia-Echeverria C and Sellers WR: Drug
discovery approaches targeting the PI3K/Akt pathway in cancer.
Oncogene. 27:5511–5526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yu P, Laird AD, Du X, Wu J, Won KA,
Yamaguchi K, Hsu PP, Qian F, Jaeger CT, Zhang W, et al:
Characterization of the activity of the PI3K/mTOR inhibitor XL765
(SAR245409) in tumor models with diverse genetic alterations
impacting the PI3K pathway. Mol Cancer Ther. 13:1078–1091. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Papadopoulos KP, Tabernero J, Markman B,
Patnaik A, Tolcher AW, Baselga J, Shi W, Egile C, Ruiz-Soto R,
Laird AD, et al: Phase I safety, pharmacokinetic, and
pharmacodynamic study of SAR245409 (XL765), a novel, orally
administered PI3K/mTOR inhibitor in patients with advanced solid
tumors. Clin Cancer Res. 20:2445–2456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jänne PA, Cohen RB, Laird AD, Macé S,
Engelman JA, Ruiz-Soto R, Rockich K, Xu J, Shapiro GI, Martinez P,
et al: Phase I safety and pharmacokinetic study of the PI3K/mTOR
inhibitor SAR245409 (XL765) in combination with erlotinib in
patients with advanced solid tumors. J Thorac Oncol. 9:316–323.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li Z, Yan S, Attayan N, Ramalingam S and
Thiele CJ: Combination of an allosteric Akt Inhibitor MK-2206 with
etoposide or rapamycin enhances the antitumor growth effect in
neuroblastoma. Clin Cancer Res. 18:3603–3615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Johnsen JI, Segerström L, Orrego A, Elfman
L, Henriksson M, Kågedal B, Eksborg S, Sveinbjörnsson B and Kogner
P: Inhibitors of mammalian target of rapamycin downregulate MYCN
protein expression and inhibit neuroblastoma growth in vitro and in
vivo. Oncogene. 27:2910–2922. 2008. View Article : Google Scholar
|
|
55
|
Lee T, Yao G, Nevins J and You L: Sensing
and integration of Erk and PI3K signals by Myc. PLOS Comput Biol.
4:e10000132008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Maris JM, Hogarty MD, Bagatell R and Cohn
SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chesler L, Schlieve C, Goldenberg DD,
Kenney A, Kim G, McMillan A, Matthay KK, Rowitch D and Weiss WA:
Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn
protein and blocks malignant progression in neuroblastoma. Cancer
Res. 66:8139–8146. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Duffy DJ, Krstic A, Schwarzl T, Higgins DG
and Kolch W: GSK3 inhibitors regulate MYCN mRNA levels and reduce
neuroblastoma cell viability through multiple mechanisms, including
p53 and Wnt signaling. Mol Cancer Ther. 13:454–467. 2014.
View Article : Google Scholar
|
|
59
|
Otto T, Horn S, Brockmann M, Eilers U,
Schüttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R,
Christiansen H, et al: Stabilization of N-Myc is a critical
function of Aurora A in human neuroblastoma. Cancer Cell. 15:67–78.
2009. View Article : Google Scholar
|
|
60
|
Yao JE, Yan M, Guan Z, Pan CB, Xia LP, Li
CX, Wang LH, Long ZJ, Zhao Y, Li MW, et al: Aurora-A down-regulates
IkappaBalpha via Akt activation and interacts with insulin-like
growth factor-1 induced phosphatidylinositol 3-kinase pathway for
cancer cell survival. Mol Cancer. 8:952009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Levine AJ: p53, the cellular gatekeeper
for growth and division. Cell. 88:323–331. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Loughery J, Cox M, Smith LM and Meek DW:
Critical role for p53-serine 15 phosphorylation in stimulating
transactivation at p53-responsive promoters. Nucleic Acids Res.
42:7666–7680. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Cox ML and Meek DW: Phosphorylation of
serine 392 in p53 is a common and integral event during p53
induction by diverse stimuli. Cell Signal. 22:564–571. 2010.
View Article : Google Scholar
|
